Article Text

Download PDFPDF

Chloroquine as alternative antimalarial in systemic lupus erythematosus. Response to ‘2019 update of the EULAR recommendations for the management of SLE: don’t forget chloroquine’ by Figueroa-Parra et al
Free
  1. Antonis Fanouriakis1,
  2. George K Bertsias2,3,
  3. Dimitrios T Boumpas1,4,5
  1. 1 Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece
  2. 2 Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece
  3. 3 Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Heraklion, Greece
  4. 4 Laboratory of Autoimmunity and Inflammation, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
  5. 5 Joint Academic Rheumatology Program, Medical School, National and Kapodestrian University of Athens, Athens, Greece
  1. Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, 12462, Greece; afanour{at}med.uoa.gr

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Drs Figueroa-Parra et al for their interest in our paper1 and their comment regarding the value of chloroquine (CQ) as an alternative antimalarial in systemic lupus erythematosus (SLE).2 As the authors point out, there are data, mostly for older studies, to …

View Full Text

Linked Articles